UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

The New England journal of medicine, 2019-08, Vol.381 (7), p.603-613

2019

Volltextzugriff (PDF)

Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes

Nature communications, 2022-11, Vol.13 (1), p.7186-12, Article 7186

2022

Volltextzugriff (PDF)

Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects

Diabetes (New York, N.Y.), 2010-02, Vol.59 (2), p.407-415

2010

Volltextzugriff (PDF)

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression

Diabetes (New York, N.Y.), 2019-06, Vol.68 (6), p.1240-1250

2019

Volltextzugriff (PDF)

Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness

American journal of physiology. Lung cellular and molecular physiology, 2022-07, Vol.323 (1), p.L14-L26

2022

Volltextzugriff (PDF)

Weekly injection of IL-2 using an injectable hydrogel reduces autoimmune diabetes incidence in NOD mice

Diabetologia, 2021-01, Vol.64 (1), p.152-158

2021

Volltextzugriff (PDF)

Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients

PloS one, 2013, Vol.8 (12), p.e83811

2013

Volltextzugriff (PDF)

Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects

JCI insight, 2021-02, Vol.6 (3)

2021

Volltextzugriff (PDF)

ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors

Proceedings of the National Academy of Sciences - PNAS, 2011-05, Vol.108 (19), p.7938-7943

2011

Volltextzugriff (PDF)

Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state

Clinical immunology (Orlando, Fla.), 2017-08, Vol.181, p.67-74

2017

Volltextzugriff (PDF)

Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes

JCI insight, 2023-08, Vol.8 (16)

2023

Volltextzugriff (PDF)

Interconnected lineage trajectories link conventional and natural killer (NK)-like exhausted CD8+ T cells beneficial in type 1 diabetes

Communications biology, 2024-06, Vol.7 (1), p.773-14, Article 773

2024

Volltextzugriff (PDF)

CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game

The Journal of immunology (1950), 2011-09, Vol.187 (5), p.2061-2066

2011

Volltextzugriff (PDF)

Shifts in isoform usage underlie transcriptional differences in regulatory T cells in type 1 diabetes

Communications biology, 2023-09, Vol.6 (1), p.988-13, Article 988

2023

Volltextzugriff (PDF)

Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression

The Journal of clinical investigation, 2020-01, Vol.130 (1), p.480-490

2020

Volltextzugriff (PDF)

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Science translational medicine, 2015-11, Vol.7 (315), p.315ra189

2015

Volltextzugriff (PDF)

Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells

The Journal of immunology (1950), 2019-12, Vol.203 (12), p.3166-3178

2019

Volltextzugriff (PDF)

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

Science translational medicine, 2021-03, Vol.13 (583)

2021

Volltextzugriff (PDF)

Clinical and experimental treatment of type 1 diabetes

Clinical and experimental immunology, 2022-12, Vol.210 (2), p.105-113

2022

Volltextzugriff (PDF)

Clinical and experimental treatment of type 1 diabetes: Perspectives on immunopathology and Clinical and experimental treatment of type 1 diabetes

Clinical and experimental immunology, 2022-12, Vol.210 (2), p.105-113

2022

Volltextzugriff (PDF)

A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab

Diabetologia, 2024-01, Vol.67 (1), p.27-41

2024

Volltextzugriff (PDF)

Integrating Omics into Functional Biomarkers of Type 1 Diabetes

Cold Spring Harbor perspectives in medicine, 2024-07, Vol.14 (7), p.a041602

2024

Volltextzugriff (PDF)

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

Journal of autoimmunity, 2015-04, Vol.58, p.48-58

2015

Volltextzugriff (PDF)

A composite immune signature parallels disease progression across T1D subjects

JCI insight, 2019-12, Vol.4 (23)

2019

Volltextzugriff (PDF)

1 – 25 von 542

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(489)
Mit Volltextzugriff
(459)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(308)
Life Sciences & Biomedicine
(251)
Humans
(180)
Female
(89)
Male
(81)
Adult
(59)
Animals
(55)
Immunology
(44)
Middle Aged
(43)
Physical Sciences
(36)
Diabetes
(34)
Adolescent
(32)
Science & Technology - Other Topics
(32)
Young Adult
(32)
Child
(29)
Multidisciplinary Sciences
(28)
Aged
(27)
Diabetes Mellitus
(27)
Medicine, Research & Experimental
(27)
Research & Experimental Medicine
(27)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes

Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes

Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression

Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness

Weekly injection of IL-2 using an injectable hydrogel reduces autoimmune diabetes incidence in NOD mice

Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients

Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects

ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors

Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state

Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes

Interconnected lineage trajectories link conventional and natural killer (NK)-like exhausted CD8+ T cells beneficial in type 1 diabetes

CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game

Shifts in isoform usage underlie transcriptional differences in regulatory T cells in type 1 diabetes

Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

Clinical and experimental treatment of type 1 diabetes

Clinical and experimental treatment of type 1 diabetes: Perspectives on immunopathology and Clinical and experimental treatment of type 1 diabetes

A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab

Integrating Omics into Functional Biomarkers of Type 1 Diabetes

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

A composite immune signature parallels disease progression across T1D subjects

Suchergebnisse filtern